Treating lupus symptoms to a clear goal
Part of Immune system & allergy, Skin clinical trials.
This study looks at a “treat-to-target” approach for people with systemic lupus erythematosus (SLE) to help control symptoms to a specific goal. It may help guide medication changes when lupus is not fully calm yet.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of lupus (SLE), meeting standard criteria
- You are 18 years or older
- Your lupus is not fully in remission right now
- You can clearly speak and understand German
- You can sign a written consent form to join
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is trying to better understand lupus (SLE) by looking at different types of the disease. It may help doctors find more personalized treatments in the future.
This trial compares two medications, telitacicept and belimumab, to see which is safer and more effective for treating lupus. It might help you if standard treatments haven't worked well for you.
This study tests whether a specific lupus “low disease activity” target (called LLDAS) works the same way in people across the Asia-Pacific region. It may help doctors use clearer goals to track how well lupus is controlled.
This early-phase trial tests a special immune cell therapy (UCAR T-cells) that targets two proteins (CD19 and BCMA) on the surface of lupus B cells. It is for people with difficult-to-treat lupus that affects the kidneys (lupus nephritis) who have not gotten better with standard treatments.
This trial tests a medicine called Telitacicept to see if it can prevent lupus flares in people whose disease is currently mild or stable. It may be a good option if you want to keep your lupus under control and avoid sudden worsening.
This trial tests an experimental oral tablet for people with systemic lupus erythematosus. It aims to see if the new medicine can help reduce lupus symptoms when added to your current standard treatment. Participants will receive the study drug and be monitored closely.
Hear when a new Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.